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ABSTRACT
Purpose Estradiol (E2)-loaded poly(L-lactide-co-glycolide-
trimethylenecarbonate) (P(L-LA:GA:TMC)) rods with shape-
memory were developed for the treatment of neurodegener-
ative diseases. Usefulness of the extrusion method in the
obtaining process was also considered. The influence of struc-
tural and surface properties during hydrolytic degradation
was developed. The possible therapeutic aspect of rods with
E2 was determined.
Methods The extruded rods were incubated in a PBS solu-
tion (pH 7.4, 37°C, 240 rpm). The amount of released E2
in vitro conditions was estimated by UV-VIS method. The
following methods in the degradation of rods were applied:
NMR, DSC, FTIR, GPC, SEM, and optical microscopy.
Changes in water uptake and weight loss were also deter-
mined. In vivo study was performed on rats. Measurements of
E2 level were performed before and after ovariectomy of rats
using ELISAmethod. A sample of tissue adjacent to the site of
the rod implantation was analysed under an optical
microscope.
Results A stable and steady degradation process ensured
zero-order release of E2. The in vivo study indicated a signifi-
cant increase in the E2 level in serum after ovariectomy.
Moreover, structural and surface features indicated that the
extrusion method was appropriate for obtaining E2-loaded
rods.
Conclusions Shape-memory P(L-LA:GA:TMC) rods with E2
are an adequate proposal for further research in the field of
neurological disorders.
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D Molecular weight distribution
DSC Differential scanning calorimetry
E2 17-β-estradiol
FGG Molar percentage of glycolidyl units
FLL Molar percentage of lactidyl units
FTIR Fourier transform infrared spectroscopy
FTMC Molar percentage of carbonate units
GPC Gel permeation chromatography
k0 Zero-order release constant (release rate)
lGG Average length of glycolidyl blocks
lLL Average length of lactide blocks
lTMC Average length of carbonate blocks
Mn Molecular weight




PBS Phosphate buffered saline
PLGA Poly(lactide-co-glycolide)
Q0 Initial amount released in time t=0
Qt Cumulative amount released in time t
SEM Scanning electron microscopy
Tg Glass transitions temperature
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Zr(Acac)4 Zirconium (IV) acetylacetonate
INTRODUCTION
17-β-estradiol (E2) is an important hormone that regulates
many functions in the body. This hormone’s reproductive role
has extensively been described in the past few years.
Individual therapeutic problems require various ways, periods
and places of administration. For this reason, E2 is available in
various pharmaceutical formulations, e.g. as oral tablets, vag-
inal tablets, or as transdermal therapeutic systems (1,2).
However, recent studies have suggested that E2 may exhibit
neuroprotective and antiapoptotic activity in the nervous sys-
tem. Animal studies have shown that chronic E2 depletion
increased injury size in the brain. Exogenous administration
of E2 reduced infarct size following cerebral ischemia in cases
of ovariectomized female rats and mice. Likewise, female ro-
dents had greater survival rates, smaller infarct volume and
lower cell loss as compared to males (3–5). Moreover, it was
shown that the E2 level is related to both incidence and pro-
gression of various neurological disorders in humans and plays
especially a protective role in neurodegenerative diseases (6).
In the future, E2 replacement therapy may be administered in
various neurodegenerative disorders in order to diminish the
extent of disease-related brain damage or to design effective
neuroprotective agents that can be administered in clinical
practice. Hence, novel possibilities in E2 therapy should influ-
ence the development of drug delivery systems. The therapy
of neurological disorders requires sustained release of the drug
substance, therefore known “classical” drug formulations with
E2 may be insufficient for this purpose. To this moment, de-
velopments in drug formulation technology to block estrogens,
hormonal contraception and hormone replacement therapy
have been observed (7), e.g. implant rods, microspheres, vag-
inal ring, thermosensitive gel, hormone-DNA complexes, and
a delivery system based on cationic liposomes (8–11).
For this purpose, aliphatic polyesters have been recom-
mended most often, i.e. polylactic acid (12,13), poly(lactide-
co-glycolide) (PLGA) (14–16), poly-ε-caprolactone (12), as
well as poly-ε-caprolactone/ PLGA blends (8).
The preferred features for sustained release of E2 are safe-
ty, low invasiveness and regular release of the drug substance.
In this work, implantable rods were developed based on an
innovative bioresorbable terpolymer poly(L-lactide-co-
glycolide-trimethylenecarbonate) P(L-LA:GA:TMC) with
shape-memory (17,18) and synthesized with the use of a low-
toxic initiator of polymerization, i.e. zirconium (IV) acetylac-
etonate (Zr(Acac)4) (19).
The use of an initiator exhibiting low toxicity seems to be
particularly important in the case of drug carriers for
prolonged release – with regard to its possible interactions
with tissues. Commercially available polyesters and
polyestercarbonates are commonly synthesized using stannous
compounds as initiators. However, they are relatively toxic
(20). Zr(Acac)4 seems to be a promising alternative, and its
low biological toxicity as compared to stannous octanoate
has been confirmed (21). Copolymers and terpolymers obtain-
ed with this initiator were characterized in detail in a previous
study (18,22). Moreover, the Zr(Acac)4 initiator makes it pos-
sible to achieve a similar chain microstructure of polymeric
materials based on lactidyl, glicolidyl, carbonate and caproyl
monomers such as stannous octanoate and allows to obtain
high-molecular-weight copolymers with good mechanical
properties (23,24).
The biodegradable shape-memory terpolymer pro-
posed in this study may reduce invasiveness and influence
regular release. Generally, shape-memory polymers are
the most promising solution in biomedical applications
(25,26). They have found application mainly in the pro-
duction of drug-eluting stents. They are used in the treat-
ment of arterial stenosis and in the prevention of resteno-
sis. For this purpose, acetylsalicylic acid, dexamethasone,
and mitomycin C with curcumin were proposed (27,28).
In stents, shape-memory polymers play a double role, i.e.
in the maintenance of tissues and in drug delivery.
However, other solutions besides stents are also possible.
In this work, a thermally sensitive P(L-LA:GA:TMC) ter-
polymer was used which is able to move from a tempo-
rary fixed shape to the original permanent shape upon
exposure to a thermal stimulus (18). Therefore, optimiza-
tion of treatment of neurodegradative diseases by reduc-
ing invasiveness and the burst effect may be guaranteed.
The burst effect is a phenomenon that is caused by solvent
penetration of the surface. Our concept assumes a reduc-
tion in the surface size and thus a reduction of the burst
effect ipso facto. The proposed rods will possess a smaller
diameter and greater length before implantation as well as
a greater diameter and smaller length after implantation,
therefore reduction of both the surface size and invasive-
ness will be possible. Additionally, biodegradability allows
to avoid explantation.
The aim of this work was to study P(L-LA:GA:TMC) rods
with shape-memory containing E2 for the treatment of neu-
rodegenerative diseases. Usefulness of the extrusionmethod in
the obtaining process was also considered on the basis of E2
and P(L-LA:GA:TMC) thermal properties. The study was
performed in vitro and in vivo. In the former, the influence
was tested of the rods’ structural and surface properties on
E2 release during hydrolytic degradation. In the latter, the
possible therapeutic aspect was determined of P(L-
LA:GA:TMC) rods with E2.
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MATERIALS AND METHODS
Polymer
A shape-memory terpolymer P(L-LA:GA:TMC) with a ratio
of 57:19:24 (59.0 kDa) and an average length of lactidyl (lLL),
glycolidyl (lGG) and carbonate (lTMC) blocks as 4.1, 1.1 and 1.5,
respectively, was synthesized with the use of a low-toxic initi-
ator Zr(Acac)4 (Sigma-Aldrich) at the Centre of Polymer and
Carbon Materials of the Polish Academy of Sciences in
Zabrze according to a previously developed methodology
(19).
Extrusion Process
P(L-LA:GA:TMC) was used to prepare rods containing 10%
w/w of E2 (Sigma, USA) by the hot melt extrusion method.
Before the process, raw terpolymer was dried on air and sub-
jected to grinding at a temperature of −196°C in a cryogenic
mill (6870 SPEX, USA). Then E2 was introduced to the
milled terpolymeric material. The mixture was vortexed and
subsequently placed for 14 days in a vacuum oven with a
temperature of 23°C and a pressure of 80 mbar. The mixture
of P(L-LA:GA:TMC) and E2 was fed to an extruder cylinder
heated to 105°C. This process was carried out in a co-rotating
twin screw extruder (Minilab, Thermo-Haake, GE) using a
plasticizing screw rotational speed of 20 rpm.
For the in vitro model, the molten mixture was extruded
through a 0.7 mm diameter die. Themolded rod was received
on a chilled roll. Afterwards, rods 1 mm in diameter and
10 mm in length were formulated. For the in vivo model the
mixture was extruded through a 1.0 mm diameter die in the
same conditions as previously. The final product was a rod
1.5 mm in diameter and 10 mm in length.
In Vitro Study
The In Vitro Degradation Process of Terpolymer Rods
The rods were placed in a PBS (phosphate buffered saline)
solution (pH 7.4) (Sigma-Aldrich) and incubated under con-
stant conditions at a temperature of 37°C and shaking at
240 rpm during 113 days.
E2 Release in the In Vitro Study
The amount of released E2 was estimated by the UV-VIS
method. The supernatants were freeze-dried and the dry mass
of samples was dissolved in 1 ml of methanol. Optical absorp-
tion measurements of the solutions were performed at room
temperature on a V-570 double-beamUV-Visible/NIR spec-
trometer (Jasco Analytical Instruments, USA). A deuterium
lamp was used as a source of ultraviolet and a halogen lamp
was used for the visible and near-infrared parts of the light
spectrum.
Absorption spectra of E2 dissolved in pure methanol were
recorded with the use of quartz cells within a spectral range
from 200 to 230 nm, where the absorption bands were ob-
served. The main absorption band of E2 was at 203.5 nm; a
calibration curve was prepared for this band and the calibra-
tion equation was estimated.
Polymer Composition and Chain Microstructure Study
Both the composition and chain microstructure study of P(L-
LA:GA:TMC) samples were determined by nuclear magnetic
resonance spectroscopy (NMR). Spectra were recorded using
a Bruker-Avance II Ultrashield Plus spectrometer operating at
600 MHz (1H) and 150 MHz (13C) using DMSO-d6 as a
solvent, with a 5-mm sample tube. 1H NMR spectra were
obtained with 32 scans, 11 μs pulse width and 2.65 s acquisi-
tion time, 13C NMR spectra were obtained with 20,000 scans,
9.4 μs pulse width and 0.9 s acquisition time. Signals observed
in 1H and 13C NMR spectra were assigned to the appropriate
sequences in the polymer chain according to a previously de-
scribed procedure (29). The content of the monomer units of
lactide (FLL), glycolide (FGG), and carbonate (FTMC) as well as
lLL, lGG and lTMC in the terpolymer chain were calculated.
Thermal Study
Thermal analysis of P(L-LA:GA:TMC) and E2 samples was
carried out by means of the differential scanning calorimetry
(DSC) method. The TA DSC 2010 apparatus (TA
Instruments, New Castle, DE) was used during the measure-
ment. The instrument was calibrated with high-purity indium
and gallium and worked under a nitrogen atmosphere (flow
rate 50 ml/min).
The terpolymer material was heated at a rate of
20°C/min. During the first run the rod samples were
heated to 200°C, then the melted samples were rapidly
cooled to −20°C. At the second run, the rods were heat-
ed within a range of −20 to 200°C. The glass transition
temperature (Tg) was determined as the midpoint of the
heat capacity change of the amorphous sample, from the
second heating run.
However, the DSC measurements for E2 were performed
as follows: (i) first heating run at 20°C/min, (ii) cooling run at
20°C/min, (iii) second heating run after cooling at 20°C/min,
and (iv) second heating run after quenching.
E2 - P(L-LA:GA:TMC) Interaction Study
The transmission technique of Fourier transform infrared
spectroscopy (FTIR) was used to determine the E2 - P(L-
LA:GA:TMC) interaction. Infrared spectra were recorded
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on a DIGILAB FTS-40A Fourier transform infrared spec-
trometer (Bio-Rad, USA) in the range of 4000–400 cm−1 at
a resolution of 2 cm−1 and for an accumulated 32 scans.
The E2 sample was analyzed in the form of pellets in po-
tassium bromide, the other compounds were analyzed as films
after dissolving in acetone and evaporating onto potassium
bromide windows.
Molecular Weight and Molecular Weight Distribution Study
Molecular weight (Mn) and molecular weight distribution (D)
of the samples were determined by gel permeation chroma-
tography (GPC) using a Viscotek Rimax chromatograph with
two Viscotek 3580 columns and a Shodex SE 61 detector.
The process was carried out with chloroform as a solvent with
a flow rate of 1 ml/min. The molecular weights were calibrat-
ed with polystyrene standards.
Water Uptake and Weight Loss Study
Changes in the water uptake (WU) and weight loss (WL) for
P(L-LA:GA:TMC) rods during the degradation process were
calculated according to the following equations:
WU %½  ¼ Mwe t−Mdry
 
=Mwe t
  100 ð1Þ
WL %½  ¼ M0−Mdry
 
=M0




Mwet wet mass of rod
Mdry dry mass of rod
M0 initial mass of rod.
Morphology Study of Drug Formulation
Both the morphology of the surface and cross-section of the
P(L-LA:GA:TMC) rod with E2 were characterized by optical
and scanning electron microscopy (SEM).
The optical microscope Carl Zeiss (Opton-Axioplan, PL)
was used for structure identification of the surface and cross-
section of the P(L-LA:GA:TMC) rod with E2 at a magnifica-
tion of ×200.
Electron micrographs were obtained using a scanning
electron microscope (Quanta 250 FEG, FEI Company,
USA) operating with an acceleration voltage of 5 kV un-
der low vacuum conditions (80 Pa) from secondary elec-
trons collected by a Large Field Detector. The samples
were mounted on microscope stubs with the use of
double-sided adhesive carbon tape.
In Vivo Study
Sterilization Process of the Rods
Sterilization of the rods was performed using an electron
beam accelerator (10 MeV, 360 mA). The absorbed dose
was 25 kGy. Sterilization was conducted at the Institute of
Nuclear Chemistry and Technology of the Center for
Radiation Research and Technology (Certificate No. 457/
2014/E).
Animal Model
The experiment protocol was approved by the Local Ethics
Committee for Animal Experimentation of the Medical
University of Silesia, Katowice (Permission No. 10/2015).
Fourteen adult female Wistar rats (weighing 250–300 g) were
obtained from the Center for Experimental Medicine of the
Medical University of Silesia, Katowice. The rats were ran-
domly divided into 3 groups, i.e. (i) control (n=6), (ii) ovariec-
tomized group and treated with rods with E2 in a dose of
2.5 mg (n=4), (iii) ovariectomized group and treated with rods
with E2 in a dose of 5 mg (n=4).
The animal study was performed according to accepted
standards of animal care (i.e. National Institute of Health,
Guide for Care and Use of Laboratory Animals).
After the animals were anesthetized (i.e. ketamine
100 mg/kg and xylazine 10 mg/kg b.w.), dorsolateral inci-
sions were made on the back, both the right and left horns
of the uterus were exposed and the ovaries were carefully
removed, leaving the uterus intact.
Seven days after the ovariectomy in group 2 and group 3 of
the animals, sterilized rods (25 kGy) with E2 in doses of 2.5
and 5 mg, respectively, were implanted subcutaneously after
an incision in the back of the neck. Then the skin was sutured
with one stitch. In the control group the animals were subject-
ed only to an ovariectomy without implantation of E2 rods
and without surgical intervention.
The animals were anesthetized and blood was collected
from the ophthalmic artery for E2 concentration
measurements.
Determination of the E2 Serum Level
Measurements of the E2 level were performed before the
ovariectomy and 7, 14, 21 and 28 days after the ovariectomy
procedure. The E2 concentration in the serum was measured
using an ELISA KIT (Estradiol ELISA KIT, Demeditec
Diagnostics GMBH, Kiel, GE). All animals were deeply anes-
thetized and decapitated after 4 weeks.
Prism 5.01 software (GraphPad Software, San Diego, CA,
USA) was used for the statistical analysis. Data were presented
as mean±S.E.M. Analyses of the E2 concentration in serum
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were performed using two-way ANOVA with the Bonferroni
post hoc test. Values of p<0.05 were considered to be statisti-
cally significant.
Morphology Study of Rat Tissue
A sample of tissue adjacent to the site of the rod implantation
was removed and immediately fixed in 10% formalin solution.
After 24 h the sample was immersed in 15% saccharose solu-
tion for 6 h, and for the next 12 h in 30% saccharose solution.
After this time period the sample was fixed in special tissue
embedding medium (Thermo Scientific, USA) and was cut
with the use of a microtome into 10-micrometer-thick sections
and placed on glass slides.
All sections were fixed in xylene for 15 min and then in
96% ethanol for 15 min. After rinsing with water the sections
were stained with hematoxylin for 20 min and with eosin for
5 min. Then all sections were rinsed with water, 96% ethanol,
xylene, dried and analyzed under a microscope at a magnifi-
cation of ×40 (Ecotone EV-157, Poland).
RESULTS
Thermal Characterization of E2 and Raw
P(L-LA:GA:TMC)
DSC study of E2 and raw P(L-LA:GA:TMC) was performed
to define thermal conditions for extrusion process. For E2,
three endothermic peaks with maxima at a temperature of
122.4°C (ΔH= 55.5 J/g), 173.8°C (ΔH= 9.3 J/g), and
179.7°C (ΔH=107.5 J/g) were observed in the first heating
run at 20°C/min (20–200°C) (Fig. 1a). The first two
endotherms correspond to the partial release of hydrogen-
bonded water and the complete loss of lattice water. The third
endotherm reflected melting, thus indicating a crystalline
character. Cooling at 20°C/min of the E2 sample from the
melt revealed the presence of Tg at 79.7°C and a smallbroad
exotherm with a maximum at 139.5°C (Fig. 1b).
The second heating runs were performed for samples
cooled in various ways, i.e. by cooling at 20°C/min and by
quenching (Fig. 1c, Fig. 1d). In the first case, Tg was observed
at 82.2°C with the presence of one exothermic peak at
132.6°C, and the next two endothermic peaks were noted at
167.9°C and 179.4°C. In the second case, Tg was observed at
the same value followed by double crystallization exothermic
peaks (130.9°C and 157.8°C) and one endothermic peak at
179.5°C.
The thermal analysis of raw powder of P(L-LA:GA:TMC)
revealed no significant endothermal and exothermal events
during the first heating run (Fig. 1e). Tg determined during
the second heating run at 20°C/min was 42.6°C after previ-
ous cooling at 20°C/min (Fig. 1f).
E2 - P(L-LA:GA:TMC) Interaction Study
The FTIR spectrum of E2 revealed two bands in the region of
3600–3100 cm−1, i.e. the first band at 3445 cm−1 and the
second, broader band at 3230 cm−1 (Fig. 2a). These bands
correspond to the stretching vibrations of the hydroxyl group
and derive from OH groups of E2 molecules as well as from
hydrogen-bonded and lattice water.
For P(L-LA:GA:TMC), a band at 3503 cm−1 was ob-
served, which may be interpreted as an overtone of the stron-
gest intensity band at 1757 cm−1 resulting from the stretching
vibrations of the C=O ester group (Fig. 2b).
Both for E2 and P(L-LA:GA:TMC), bands in the region of
3000–2800 cm−1 (stretching mode), 1480–1350 cm−1 and
1100–800 cm−1 (deformations) and attributed to the vibra-
tions of the CH2 and CH group were observed.
Bands characteristic of the stretching vibrations of the C-
O-C and C-OH groups appeared in the region of 1250–
1050 cm−1. An aromatic ring present in the E2 compound
was absorbed in the region of 3100–3000 cm−1 (stretching of
C-H), 1610–1480 cm−1 (stretching of phenyl ring), 1100–
800 cm−1 (C-H deformations).
In the spectrum of the P(L-LA:GA:TMC) rod with E2,
bands characteristic of E2 were not observed due to its low
content. For that reason, the spectrum of the mixture of P(L-
LA:GA:TMC) and E2 in a ratio of 1:1 was recorded.
Morphology Study of Drug Formulation
Observation of the P(L-LA:GA:TMC) rod with E2 performed
by optical microscopy revealed a non-homogeneous charac-
ter. Particles of various size were visible in the cross-section
Fig. 1 DSC curves of the first heating run for E2 (a), cooling run for E2 (b),
second heating run after cooling at 20°C/min for E2 (c), second heating run
after quenching for E2 (d), first heating run for P(L-LA:GA:TMC) (e) and
second heating run after cooling at 20°C/min for P(L-LA:GA:TMC) (f).
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(Fig. 3a) and on the surface (Fig. 3b). Some examples of par-
ticles were marked in figures with arrows.
In Vitro Study
E2 Release from P(L-LA:GA:TMC) Rods
A total of 718.45±4.85 μg (n=10) of E2, i.e. 100% of the
introduced substance, was released from the P(L-
LA:GLA:TMC) rods during a period of 113 days. A zero-
order kinetic model was used to describe the release of E2
(Fig. 4).
Q t ¼ Q 0 þ k0t; ð3Þ
where
Qt cumulative amount in μg of E2 released in time t
Q0 initial amount in μg of E2 released in time t=0
k0 zero-order release constant (release rate) (μg/day).
The plot of Qt versus t is a straight line with a slope of k0.
The straight line of linear regression analysis indicates a zero-
order release kinetic of E2 with an R2 value of 0.9889. The
zero-order release constant k0 was 5.15 μg per day. The initial
amount of E2 released after the first day (for t=0) was at a
level of 8.9±0.0016%.
Polymer Composition and Chain Microstructure Changes
Changes in the monomer unit distribution in the polymer
chain of P(L-LA:GA:TMC) during the degradation process
were determined on the basis of 1H NMR spectra (Fig. 5).
P(L-LA:GA:TMC) initially contained a predominant FLL
(above 58 mol%) as well as a low of the FGG (~18 mol%)
and FTMC units (~24 mol%) (Table I).
Fig. 2 Infrared spectra of the sum of raw powder of P(L-LA:GA:TMC) and E2 spectra (a), mixture of P(L-LA:GA:TMC) and E2 (b), P(L-LA:GA:TMC) rod with
E2 (c), raw powder of P(L-LA:GA:TMC) (d) and E2 (e). No differences between spectrum a and spectrum b indicate a lack of E2- P(L-LA:GA:TMC) interactions.
Fig. 3 Optical microscopy images
of the cross-section (a) and surface
(b) of P(L-LA:GA:TMC) with E2
(magnification× 200).
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The NMR study revealed differences in monomer unit
distribution during the 113-day period of incubation.
Enhanced degradation of the glycolidyl units was noted: FGG
decreased from 17.6mol% at the beginning of the experiment
to 11.5 mol% at the last measured stage of the degradation
process. In the same period, FLL increased and FTMC remained
at the same level (Table I).
On the basis of P(L-LA:GA:TMC) 13C NMR spectra,
changes in the chain microstructure were analyzed and de-
scribed (Fig. 6). The analysis revealed a meaningful, steady
decrease of lLL during degradation. In the case of the lGG
and lTMC, no changes were noticeable during the whole pro-
cess of degradation (Table I). After 70 days of the experiment,
13C NMR analysis was not possible due to an unsatisfactory
resolution of the spectra connected with an advanced disinte-
gration process of the terpolymer. Degradation of P(L-
LA:GA:TMC) proceeded steadily.
Thermal Properties Study
DSC study of E2-loaded P(L-LA:GA:TMC) rods was per-
formed to describe degradation process.
An analysis of the first run of rods revealed significant
changes in the parameters, such as Tm and ΔH during
113 days of degradation. In the period of 0 to 15 days,
only one thermal event at DSC scans with high oscilla-
tion in the values of Tm2 and ΔH2 was observed (Fig. 7a).
Additional endothermic peaks appeared (Tm1) on the
29th day of the degradation process. In the period of
the 29th to 57th day, a decrease in the Tm1, Tm2 values
was observed. Later, an increase up to day 113 was not-
ed. It should be pointed out that in the same time period
an increasing trend was observed for ΔH1. In the case of
ΔH2, oscillation in the value was noted between the 29th
and 57th day, however, from the 57th day onwards a
phenomenon analogical to ΔH1 was observed.
The second heating revealed noticeable changes in Tg
(Fig. 7b). A significant decrease in Tg, from 40.2 to 22.6°C,
was noted after 57 days. After this time the value of Tg in-
creased to 41.3°C.
Molecular Weight and Molecular Weight Distribution Study
The GPC analysis revealed a gradual decrease of Mn during
113 days of degradation, from 45.8 to 0.8 kDa (Fig. 8). The
most significant drop was observed in 43 and 57 day.
Molecular weight distribution (D) was also determined.
Dispersity increased from 1.9 to 2.5 after 57 days of incuba-
tion, then it decreased to 1.9 during the next 42 days. After
this time D increased again to 3.5 at the end of the process.
Water Uptake and Weight Loss
Changes were noted in both the WU and WL values. An
increasing trend for WU was observed during 113 days.
During this period the amount of absorbed water was
76.5%. The weight dropped by 86.7% during the deg-
radation process. The most significant changes in these
parameters were observed after 57 day. Moreover, the
correlation between these two parameters was 0.99
(Fig. 8).
SEM Study
The outer morphology of native E2 rods performed by using
the SEM method exhibited a solid surface. The inner mor-
phology of native E2 rods also showed a solid structure, how-
ever, some layers and delamination as a result of preparing the
cross-section were visible (Fig. 9).
SEM observations were performed for 85 days. The
degradation indicated changes in both the outer and
Fig. 4 In vitro cumulative release profile of E2 from P(L-LA:GA:TMC) rods
(n=10) fitted in the zero-order release.
Fig. 5 H1 NMR spectra (600 MHz, DMSO-d6) of the P(L-LA:GA:TMC)
rod with E2 during 113 days of degradation (methine proton region of the
lactidyl units (1) and methylene proton region of the glycolidyl (2) and carbon-
ate units (3)).
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inner morphology of the rods. The surface started to
differ in its morphological features, i.e. surface roughness
and recesses were appeared. No evident porous surfaces,
slits and cracks were observed on the surface during deg-
radation (Fig. 9). However, the primary surface disap-
peared in 43 day.
The inner morphology revealed a solid structure from the
beginning. Delamination was also visible as a result of prepar-
ing the cross-section. Because of rod features there was not
possible to obtain cross-section from 43 day.
In Vivo Study
Therapeutic Effect
The E2 concentration in serum was measured for 4 weeks as
effectively drawing blood from the ophthalmic artery was not
possible. The formation of a scar was observed in the puncture
site (Fig. 10).
In each period after ovariectomy the E2 level in serum was
statistically significant for animals with implanted rods with
E2. The highest increase in the E2 concentration was noted
14 days after implantation of each kind of rod, i.e. rods with
doses of 2.5 and 5 mg. Rods with a dose of 5 mg caused a
greater increase of the E2 concentration than rods with a dose
of 2.5 mg. Moreover, it should be pointed out that the E2
levels were highly diversified in individual animals after rod
implantation in the same time period (Fig. 10).
Tissue Morphology
A microscopic study from the place of explantation revealed
connective tissue with a visible fibroblast nucleus and adipo-
cytes. No inflammation, necrosis and exudate were visible in
tissue adjacent to the site of the rod implantation (Fig. 11a).
Microscopic analysis revealed no signs of inflammation in the
tissue.White blood cells and necrosis were not observed in any
of the samples (Fig. 11b).
DISCUSSION
In this paper a novel conception has been developed in drug
technology based on a terpolymer with shape-memory









lLL lGG lTMC 1st run 2nd run Mn (kDa) D WU (%) WL (%)
Tm1 (°C) ΔH1 (J/g) Tm2 (°C) ΔH2 (J/g) Tg (°C)
0 57.9 17.6 24.5 4.2 1.1 1.5 ND ND 126.7 21.3 40.2 45.8 1.9 0 0
1 57.3 17.7 25.0 4.1 1.1 1.6 ND ND 139.4 5.1 39.4 43.1 1.9 0.9 0
15 57.1 17.6 25.3 3.8 1.1 1.5 ND ND 132.0 13.3 38.7 33.4 1.9 4.0 0.5
29 57.5 17.5 25.0 3.8 1.1 1.5 86.6 1.4 141.1 7.9 38.2 18.8 1.9 6.8 2.2
43 57.4 17.2 25.3 3.2 1.2 1.5 81.4 4.8 136.4 9.9 35.7 8.8 2.3 8.7 3.4
57 57.1 14.7 28.2 3.1 1.2 1.6 71.1 4.1 116.6 1.5 22.6 1.4 2.5 12.9 4.9
71 58.2 13.2 28.7 2.5 1.1 1.6 75.8 8.5 137.2 16.1 25.3 1.3 1.9 34.3 31.0
85 62.7 12.3 25.0 ND ND ND 85.4 13.9 139.7 21.3 34.9 1.2 1.9 38.9 38.3
99 64.2 11.9 23.9 ND ND ND 88.6 17.5 145.8 25.6 38.7 1.1 1.9 66.1 68.8
113 64.0 11.5 24.5 ND ND ND 94.9 18.9 151.3 29.9 41.3 0.8 3.5 76.5 86.7
FLL molar percentage of lactidyl units, FGG molar percentage of glycolidyl units, FTMC molar percentage of carbonate units, lLL average length of lactidyl blocks, lGG
average length of glycolidyl blocks, lTMC average length of carbonate blocks, Tm1 and Tm2 melting temperatures, ΔHm1 and ΔHm2 enthalpies of melting, Tg glass
transition temperature, Mn molecular weight, D molecular weight distribution, WL weight loss, WU water uptake, ND non-detected
Fig. 6 13CNMR (150MHz, DMSO-d6) of the P(L-LA:GA:TMC) rod with E2
during113daysof degradation (methine carbon regionof the lactidyl units (LL) and
methylene carbon regionof the glycolidyl (GG) and carbonateunits (T)).3-TLLLT, 5-
GLLT+GLLLT, 6-TLLLL+LLLLT, 7-LLLL, 8-LLGG, 9-GLG, 10-TT’G+GGT’GG+
TGT’GG, 11-GGTT, 12-GGT’GT+GT’GT, 13-GGT’GT+TT’L+LTT’, 14-TT’T+
TTT’+TT”G, 15-TT’GG, 17-TGT+TGGL+TGGT, 18- LGGGT+TGGGT+GGGGT,
19-TT’L+LT’T, 20-LT’L+LT”L, 21-GGT’T, 22-GGT”GT+GGT”GG, 23-TGT”GG+
TGT’GT, 24-TGGGG+TGG, 25-TGGT, 26-GGLL, 27-GGGG.
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synthesized with the use of a low-toxic initiator. This formu-
lation may guarantee lower invasiveness, regular release and
lower irritation of tissues and may thus be suitable as a future
treatment strategy for neurological disorders.
Designing the pharmaceutical formulation is the most im-
portant stage in the development of novel formulations.
Thermoplastic polymers can be processed in various ways.
One of these is the extrusion method. Solid formulations
should be preferred for prolonged release so that explantation
is possible in emergency cases. A rod is one of these applied
formulations. It may be administered by needle from a pre-
filled syringe or by an implanter.
It should be pointed out that there is a high risk of thermal
degradation of the drug substance and polymer carrier during
this extrusion process. Therefore, in this paper thermal anal-
ysis was performed for E2 and P(L-LA:GA:TMC) to deter-
mine the processing conditions.
It was noticed that the extrusion process of P(L-
LA:GA:TMC) rods with E2 may be carried out at a temper-
ature of 105°C. Maintaining stable conditions at this value is
important for E2. Hydrogen-bonded water and lattice water
in E2 will be maintained and changes between polymorphic
crystal forms of E2 will not occur (Fig. 1) (30,31). Therefore,
proposed conditions proved to be suitable.
Additionally, these conditions will not significantly
change the terpolymer properties. The DSC curves of
P(L-LA:GA:TMC) raw powder did not revealed any sig-
nificant thermal event, which indicated an amorphous
character of the applied terpolymer (Fig. 1). Moreover,
it should be pointed out that the use of crystalline drug
substance create a non-homogeneous formulation with
amorphous polymer. Crystalline character was revealed
for E2 and non-homogenuous structure of rods with E2
before degradation was showed in the observations per-
formed by optical microscopy of the rods (Fig. 3).
The effectiveness of pharmacological interventions in
the treatment of neurological disorders requires regular
drug administration, thus the application of an implant-
able drug delivery system has many advantages over oral
therapy. It has been stated that aliphatic polyesters such
as polylactic acid, PLGA, and poly-ε-caprolactone are
most often recommended in hormonal therapy with E2
(8,13–16). The release ratio depends on the degradation
mechanism. It is commonly known that degradation of
pointed aliphatic polyesters is based on bulk erosion
through hydrolysis of the ester bonds. For most sub-
stances, sigmoidal release is observed during bulk ero-
sion, however, it also depends on substance features (32).
In this paper, an almost linear E2 release with the burst
effect from P(L-LA-GA:TMC) was observed (Fig. 4).
However, this phenomenon did not influence release charac-
ter. Zero-order release mainly results, which is preferred fea-
ture from therapeutic point of view.
An analogous mechanism of E2 release, i.e. the zero-order
pattern, from the PLGA (50:50) carriers was revealed by an-
other study. Optimal release was revealed for polymers with a
molecular weight of 45.0 kDa. In that study the terpolymer
possessed a similar value of this parameter. Moreover, the
authors claimed that the release rate of E2 was dependent
on the molecular weight of the polymer carrier and its chain
Fig. 7 DSC curves of the first run (a) and second run (b) for E2-loaded P(L-LA:GA:TMC) rods after 0, 1, 15, 29, 43, 57, 71, 85, 99 and 113 days of degradation.
Fig. 8 Comparison ofMn loss [%], WU [%] and WA [%] rise of E2-loaded
P(L-LA:GA:TMC) rods after 0, 1, 15, 29, 43, 57, 71, 85, 99 and 113 days of
degradation.
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composition. They proved that an increase inMn in the range
of 14.5–213 kDa of the PLGA carriers caused a significant
decrease in the release rate of E2 (33). It should be pointed
out that the P(L-LA:GA:TMC) applied here possessed Mn
with a similar value, i.e. 59 kDA. A similar releasing profile
was also presented in other studies (34,35).
In this paper, terpolymer P(L-LA:GA:TMC) was ap-
plied. In the case of LA and GA in copolymers, degra-
dation takes place in the bulk. However, the degradation
of aliphatic P(TMC) undergoes surface erosion.
Therefore, the release process is controlled both by the
structure and surface. It may influence the release mech-
anism controlled more by the surface than in the case of
the PLGA copolymer.
Furthermore, it should be emphasized that zero-order re-
lease results from some given feature. The first is a lack of
interaction between substance and polymer, which was indi-
cated in this study. A comparison of the E2 - P(L-
LA:GA:TMC) infrared spectrum with the algebraic sum of
P(L-LA:GA:TMC) and E2 spectra showed no significant dif-
ferences in all regions of the spectra (Fig. 2). It may thus be
stated that the form of the composite does not favor linear
release. However, a key role is played by the lack of interac-
tions of the drug substance with the polymer.
There is no doubt that the amorphous character of the
applied terpolymer will favor this release model. In the first
heating run no endothermal events were noted. However, the
loading of E2 into P(L-LA:GA:TMC) influenced the
Fig. 9 SEM images of P(L-LA:GA:TMC) rods with E2 degraded for 0 days (picture number-magnification) (a1-×115, a2-×423, a3-×2666, a4-×10436, b1-
×238, b2-×1131, b3-×2468, b4-×9870), 1 day (c1-×500, c2-×1000, c3-×2500, c4-×10000, d1-×500, d2-×1000, d3-×2500, d4-×10000), 15 days
(e1-×500, e2-×1000, e3-×2500, e4-×10000, f1-×500, f2-×1000, f3-×2500, f4-×5000, 29 days (g1-×500, g2-×1000, g3-×2500, g4-×10000, h1-
×500, h2-×1000, h3-×2500, h4-×10000), 43 days (i1-×377, i2-×1000, i3-×2293, i4-×7500), 57 days (j1-×500, j2-×1000, j3-×2500, j4-×5000),
71 days (k1-×500, k2-×500, k3-×1000, k4-×5000), 85 days (l1-×183, l2-×755, l3-×2500, l4-×8409).
Fig. 10 Measurements of serum E2 concentrations. Two-way ANOVA with
the Bonferroni post hoc test was applied for comparison between the non-
implanted control group (n=4), ovariectomized group, and animals with
2.5 mg (n=4) or 5 mg (n=6) E2 rod-treated: ***-E2 rod-implanted
5 mg group vs. control (p<0.001), *-E2 rod-implanted 2.5 mg group vs.
control (p<0.05), **-E2- rod- implanted group 2.5 mg vs. E2 rod-implanted
group 5 mg (p<0.01).
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appearance of an endotherm, which may resulted from the
presence of drug substance. It may be confirm by gradual
disappearance of this endotherm during degradation.
However, novel endotherms were noted, which may point to
the crystallization process of the amorphous terpolymer.
Generally, a stable and steady degradation was observed,
which may influence linear release. However, derogations in
release profile were also visible. Changes in the content of
monomeric units in the terpolymer were noted. Advanced
degradation was observed of glycolidyl units that were more
hydrophilic than the lactidyl units. Moreover, only a mean-
ingful steady decrease of lLL was noted during the whole pro-
cess of degradation (Table I). This phenomenon may influ-
ence the derogations in the linear character of the release
profile. In the case of the other parameters, a gradual decrease
in Tg andMn, and a gradual increase in the values ofWU and
WL were also observed during the degradation process. This
may also favor a linear release of E2 (Table I). The listed
changes are typical of the degradation processes of aliphatic
polyesters (18,36). However, the observed derogations in re-
lease profile of E2 between 57 and 92 days might result from
significant changes in Tg, Mn, WL and WU in this period
(Table I).
The morphological study performed by SEM did not re-
veal any unfavorable features, i.e. an evident porous surface or
slits and cracks which might predispose uncontrolled release
(Fig. 9).
The proposed solution of the novel E2 formulation indicat-
ed that the P(L-LA:GA:TMC) rods with E2 significantly in-
creased its level in serum after ovariectomy (Fig. 9). However,
the E2 concentration in serum in individual animals was high-
ly diversified in the same period group after implantation,
which shows that the animals reacted to the therapy in various
ways. However, it should be emphasized that E2 was still
secreted by the adrenal cortex after ovariectomy. Therefore,
the observed E2 concentration was a total level, i.e. secreted
endogenously and administered by the rods. Furthermore, no
inflammation reactions, necrosis and exudate in tissue
adjacent to the site of rod implantation were revealed
(Fig. 11), which confirmed the low toxicity of the zirconium
complexes.
CONCLUSION
In conclusion, both the in vitro and in vivo study showed that
shape-memory P(L-LA:GA:TMC) rods with E2 are an ade-
quate proposal for further research in the field of neurological
disorders and therapy. A stable and steady degradation pro-
cess ensured linear release of E2 from the rods. This guaran-
teed prolonged release independently of its concentration.
Rods may guarantee low invasiveness, regular release and
low irritation of tissue.Moreover, the application of zirconium
complexes resulted in no adverse effects caused by the poly-
mer. Usage of the extrusion method was appropriate in order
to obtain rods which allowed us to successfully apply them in
animals, thus at the same time indicating their therapeutic
applicability.
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Fig. 11 A view of rod explantation
(a – white arrow) and histopathology
of the tissue from the place of the
explanted rod (magnification× 40)
(b). Black arrows - fibroblast nucleus;
black stars – adipocytes.
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